Should I Buy OFIX? OFIX 2026 Analysis

Should You Buy Orthofix Medical Inc (OFIX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

12.800

1 Day change

0.79%

52 Week Range

20.480

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient investor: price is breaking below near-term support and the 1-month pattern read-through is negative.
Upside exists toward $14 (latest PT), but the market is still waiting for clearer evidence of sales acceleration; that timing is suggested as later (possibly into late 2026), not “right now.”
Intellectia Proprietary Trading Signals
AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend/bias: short-term bearish/weak; MACD histogram is below zero (-0.061) and only modestly contracting (selling pressure may be easing, but trend is still down).
RSI(6)=22.56 indicates deeply oversold conditions (despite the feed’s “neutral” label), which can create bounces, but oversold alone is not a reliable “buy now” trigger.
Price location vs levels: $12.68 is below S1 ($12.812) and just above S2 ($12.569) → the stock is sitting in a fragile support pocket.
Key upside reclaim needed for a cleaner entry: move back above pivot ~$13.205, then resistance ~$13.60; until then, rallies can fail into overhead supply.
Pattern-based forward read: similar candlestick setup implies ~-5.69% over the next month (near-term odds not favorable for immediate buying).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/skew: Open interest put/call ratio 0.48 (more calls than puts) → mildly bullish positioning.
Activity: today’s option volume is 0 (no real-time confirmation from trading flow), so sentiment signal is weak.
Volatility: 30D IV ~95.73 vs HV ~32.41 → options are pricing a very large move relative to realized; this often reflects uncertainty into catalysts (notably upcoming earnings).
IV percentile ~50.6 / IV rank ~33.27 → elevated absolute IV, but not extreme versus its own history.

Technical Summary

Sell

Buy

Positive Catalysts

- Earnings catalyst upcoming: QDEC 2025 earnings on 2026-03-02 (pre-market) could reset expectations if revenue growth/guide improves.
- Analyst view acknowledges improving profitability/cash flow efforts and enterprise-wide changes—if execution shows up in reported sales momentum, the stock could re-rate.
- Gross margin improved materially in the latest reported quarter (supports the “operational improvement” narrative).

Neutral/Negative Catalysts

- No recent news catalysts in the past week—nothing currently forcing a near-term re-pricing upward.
- Latest analyst initiation is only Hold; the bull case “needs evidence of accelerating sales,” which is not yet visible.
- Recent quarter still shows losses: net income and EPS both deteriorated YoY, which can cap upside until a clear inflection appears.
- Technical breakdown risk: trading below S1 and near S2 means a small additional drop can trigger further downside momentum.

Financial Performance

Latest quarter provided: 2025/Q3.
Revenue: $205.634M, +4.59% YoY (moderate growth).
Profitability: Net income -$22.795M, down -16.77% YoY (loss widened).
EPS: -0.57, down -19.72% YoY (worse).
Gross margin: 70.71%, up +6.52% YoY (clear improvement, but not yet flowing through to net profitability).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

2026-01-26: TD Cowen initiated coverage at Hold with $14 price target.
Summary of trend: only one recent rating data point provided; tone is constructive on restructuring/profitability, but cautious due to limited visibility on top-line acceleration until potentially late 2026.
Wall Street pros: operational improvement efforts, improving profitability/cash flow narrative, margin expansion.
Wall Street cons: shares likely need proof of accelerating sales; without that evidence, upside may be limited and timing uncertain.

3 Analyst Rating

Wall Street analysts forecast OFIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OFIX is 21.33 USD with a low forecast of 18 USD and a high forecast of 24 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 12.700

Low

Averages

21.33

High

Current: 12.700

Low

Averages

21.33

High

TD Cowen

Hold

initiated

$14

AI Analysis

2026-01-26

Reason

TD Cowen

Price Target

$14

AI Analysis

2026-01-26

initiated

Hold

Reason

TD Cowen initiated coverage of Orthofix with a Hold rating and $14 price target. The company is affecting enterprise-wide change while driving improving profitability and cash flow, even though its top-line acceleration is less visible today and may not be until late 2026, the analyst tells investors in a research note. TD adds that it is unequivocally positive on to-date/ongoing efforts to reshape the investment story, noting however that for the shares to "work", there needs to be evidence of accelerating sales.

Barrington

Michael Petusky

Outperform

maintain

$17 -> $18

2025-11-05

Reason

Barrington

Michael Petusky

Price Target

$17 -> $18

2025-11-05

maintain

Outperform

Reason

Barrington analyst Michael Petusky raised the firm's price target on Orthofix to $18 from $17 and keeps an Outperform rating on the shares. The company reported strong Q3 results and upped the low-end of its fiscal 2025 EBITDA outlook, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for OFIX

Unlock Now

OFIX Should I Buy

OFIX Should I Buy

Should You Buy Orthofix Medical Inc (OFIX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch